These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 10731546)

  • 1. Comparison of a single half-dose, long-acting form of gonadotropin-releasing hormone analog (GnRH-a) and a short-acting form of GnRH-a for pituitary suppression in a controlled ovarian hyperstimulation program.
    Hsieh Y; Tsai H; Chang C; Lo H
    Fertil Steril; 2000 Apr; 73(4):817-20. PubMed ID: 10731546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
    Hsieh YY; Chang CC; Tsai HD
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome of using ganirelix acetate versus a 4-day follicular phase leuprolide acetate protocol in unselected women undergoing in vitro fertilization.
    Posada MN; Vlahos NP; Jurema MW; Bracero NJ; Wallach EE; Garcia JE
    Fertil Steril; 2003 Jul; 80(1):103-10. PubMed ID: 12849810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment?
    Ren J; Sha A; Han D; Li P; Geng J; Ma C
    Fertil Steril; 2014 Jul; 102(1):75-81. PubMed ID: 24746740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous low dose leuprolide acetate depot versus leuprolide acetate for women undergoing ovarian stimulation for in-vitro fertilization.
    Tsai HD; Chen CM; Lo HY; Chang CC
    Hum Reprod; 1995 Nov; 10(11):2909-12. PubMed ID: 8747042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Impact of controlled ovarian hyperstimulation delayed, which occurs after functionally pituitary downregulation by depot GnRH agonist, on the outcome of in vitro fertilization and embryo transfer].
    Ma QH; Li SW; Huang ZY; Han ZY; Qiu DS; Han DW
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Nov; 38(6):980-3. PubMed ID: 18095601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of leuprolide acetate and triptorelin in assisted reproductive technology cycles: a prospective, randomized study.
    Orvieto R; Kerner R; Krissi H; Ashkenazi J; Ben Rafael Z; Bar-Hava I
    Fertil Steril; 2002 Dec; 78(6):1268-71. PubMed ID: 12477523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
    Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
    Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical applications of different doses of leuprorelin acetate in in vitro fertilization-embryo transfer].
    Wang L; Zhang WX; Jiang H
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):910-4. PubMed ID: 23324190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-control study on reduced-dose depot versus daily administration of gonadotrophin-releasing hormone agonists for pituitary desensitization in in vitro fertilization cycles.
    Gao J; Xu YW; Miao BY; Zhou CQ
    J Obstet Gynaecol Res; 2014 Jul; 40(7):1901-6. PubMed ID: 25056469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a "freeze all" strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg.
    Zhu X; Ye H; Fu Y
    Fertil Steril; 2017 Feb; 107(2):379-386.e4. PubMed ID: 27865446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal stimulation IVF using clomiphene citrate and oral contraceptive pill pretreatment for LH suppression.
    Branigan EF; Estes MA
    Fertil Steril; 2000 Mar; 73(3):587-90. PubMed ID: 10689017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles.
    Albuquerque LE; Saconato H; Maciel MC
    Cochrane Database Syst Rev; 2002; (3):CD002808. PubMed ID: 12137658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of three different gonadotrophin-releasing hormone analogues in an IVF programme: a prospective study.
    El-Nemr A; Bhide M; Khalifa Y; Al-Mizyen E; Gillott C; Lower AM; Al-Shawaf T; Grudzinskas JG
    Eur J Obstet Gynecol Reprod Biol; 2002 Jul; 103(2):140-5. PubMed ID: 12069736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection.
    Takeuchi S; Minoura H; Shibahara T; Tsuiki Y; Noritaka F; Toyoda N
    Fertil Steril; 2001 Sep; 76(3):532-7. PubMed ID: 11532477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization or intracytoplasmic sperm injection.
    Qin N; Chen Q; Hong Q; Cai R; Gao H; Wang Y; Sun L; Zhang S; Guo H; Fu Y; Ai A; Tian H; Lyu Q; Daya S; Kuang Y
    Fertil Steril; 2016 Aug; 106(2):334-341.e1. PubMed ID: 27114329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of a combination administration of gonadotropin-releasing hormone agonist and gonadotropins for controlled ovarian hyperstimulation in IVF program.
    Chang YS; Kim SH; Shin CJ; Kim JG; Moon SY; Lee JY
    Asia Oceania J Obstet Gynaecol; 1990 Dec; 16(4):337-45. PubMed ID: 2129188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose depot leuprolide is as efficient as daily short-acting leuprolide in ICSI cycles.
    Isikoglu M; Ozdem S; Berkkanoglu M; Jamal H; Senturk Z; Ozgur K
    Hum Reprod; 2007 Jun; 22(6):1657-61. PubMed ID: 17434884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.